Abstract Cigarette smoke contains many carcinogens that are metabolically activated through xenobiotic metabolism by phase I and II enzymes, including N-acetyltransferases 1 and 2 (NAT1 and NAT2). We investigated non-Hodgkin lymphoma risk in general and by subtype in relation to NAT1 and NAT2 genotypes and cigarette smoking in a population-based case-control study in Connecticut. Of the 535 controls, 53.1% reported ever smoking, and of the 461 cases, 55.7% reported ever smoking. We found a two-fold increased risk of T-cell lymphoma among those possessing the NAT1*10 genotype compared to those with other NAT1 genotypes; including an OR of 2.0 (95% CI: 1.0-2.4) for those heterozygous or homozygous for NAT1*10 genotypes. Rapid acetylator NAT2 phenotype increased the risk of both T-cell lymphoma (OR = 3.2; 95% CI: 1.1-9.5) and marginal zone lymphoma (OR = 3.0; 95% CI: 1.0-8.7), though these results were based on a small number of cases. When smoking status and risk of NHL was stratified by NAT1 and NAT2 genotypes, an increased risk of NHL overall was observed in current (OR = 1.7; 95% CI: 1.2-2.4) smokers without the NAT1*10 genotype but not among smokers with the NAT1*10 genotype (p-interaction \ 0.01). No association between history of cigarette smoking and risk of NHL overall was observed with any NAT2 genotype. Our results present modest evidence that acetylation rate is associated with risk of NHL for specific subtypes and that the NAT1*10 genotype is an ''at-risk'' allele. Additionally, our results suggest that the relationship between NHL and smoking status may be modified by common genetic variation in NAT1 but not NAT2. We conclude that these findings require replication in larger studies and ultimately in pooled analyses.
Introduction
There have been consistent reports of increases in the incidence and mortality due to non-Hodgkin lymphoma (NHL) during the past decades [1] [2] [3] [4] [5] [6] . The etiology of NHL, however, remains unclear with few known risk factors (i.e., severe immunosuppression resulting from diseases, treatments, and viral infections) [7] [8] [9] [10] . Tobacco products contain several carcinogenic compounds hypothesized to increase NHL risk [11] . Although smoking has been associated with several hematopoietic cancers [12] [13] [14] [15] [16] [17] [18] [19] [20] , previous results in the literature have been conflicting for NHL in general, suggesting the association may be NHL subtype specific, and in most studies any observed effect has been relatively weak [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] .
Xenobiotic-metabolizing enzymes catalyze the activation and/or deactivation of carcinogenic chemicals found in tobacco products [31, 32] . Many enzymes are genetically polymorphic and are responsible for inter-individual variation in metabolism. This variation may result in different patterns of susceptibility to the effects of smoking on cancer outcomes. N-Acetyltransferase 1 and 2 (NAT1 and NAT2) exhibit genetic polymorphisms and resulting acetylation phenotypes (slow or rapid) that are common in most populations. We therefore investigated NHL risk in general and by subtype in relation to genetic variation and subsequent acetylation rates in NAT1 and NAT2 and smoking status in a population-based case-control study of females in Connecticut, USA.
Methods
The study population has previously been described in detail elsewhere [27, 33, 34] . Briefly, from 1996 to 2000, all histologically confirmed incident female NHL cases aged 21-84 in Connecticut, alive at the time of interview and without a previous diagnosis of cancer except for nonmelanoma skin cancer, were identified through the Yale Cancer Center's Rapid Case Ascertainment Shared Resource (RCA). Of 832 eligible cases, 601 (72%) completed in-person interviews. Controls were frequency matched to cases on age (within 5-year groups) and were recruited using random digit dialing (RDD) methods for those aged \ 65, or randomly selected from the files provided by the Centers for Medicare and Medicaid Service (CMS) for those aged C65. The participation rate was 69% for RDD controls and 47% for CMS controls. The study was approved by the Institutional Review Board at Yale University, the Connecticut Department of Public Health, and the National Cancer Institute. Written, informed consent was obtained from each subject, and participation was voluntary. About 75% of the interviewed subjects provided blood samples (76.7% of cases and 74.6% of controls), and about 10% of the study subjects (11.0% of cases and 10.4% of controls) provided buccal cell samples.
DNA was extracted from blood or buccal cell samples using phenol-chloroform extraction. Genotyping was conducted at the National Cancer Institute Core Genotyping Facility (Advanced Technology Center, Gaithersburg, Maryland, USA) using validated assays on the Taqman (Applied Biosystems, Foster City, California, USA) or MGB Eclipse (Epoch Biosciences, Bothell, Washington, USA) platforms. Sequence data and assay conditions are available at http://www.snp500cancer.nci.nih.gov [35] . We selected four single nucleotide polymorphisms (SNPs) in NAT1 and six SNPs in NAT2 for genotyping. Data from the NAT1 and NAT2 SNPs genotyped in this study were used to assign the most likely NAT1 and NAT2 alleles previously identified in human populations using consensus nomenclature (http://www.louisville.edu/med school/pharmacology/NAT.html) [36] . All 10 SNPs were genotyped in blood-based DNA samples because DNA samples from buccal cell were insufficient for this analysis, yielding a population of 461 cases and 535 controls. Because of incomplete genotyping for some SNPs due to insufficient DNA, the most likely NAT alleles could not be determined for 8 cases and 7 controls for NAT1, and 5 cases and 2 controls for NAT2, yielding a final population of 453 cases and 528 controls for analyses of NAT1 genotypes, and 456 cases and 533 controls for analyses of NAT2 genotypes.
The effects of NAT1 and NAT2 nucleotide substitutions on acetyltransferase catalytic activities have been identified in human NAT1 and NAT2 allelic variants which yield reductions in substrate affinity, catalytic activity, and/or protein stability of the recombinant N-acetyltransferase allozyme which is used to determine the acetylation phenotype [37] . Both NAT1 and NAT2 genotypes exhibit genetic polymorphisms in humans corresponding to slow and rapid acetylator phenotypes. The NAT2 genotypephenotype relationship is well established. NAT2 acetylation phenotype was assigned at the University of Louisville (by DWH) based on the data obtained in vivo and in vitro on allelic variation in catalytic activity [38] . For analysis of NAT2 phenotypes, individuals homozygous for NAT2 rapid-and slow-acetylator alleles were designated as rapidand slow-acetylators, respectively; individuals possessing one rapid-and one slow-acetylator allele (heterozygotes) were designated as intermediate acetylators [39] . Rapid conjugation is hypothesized to increase risk by activating carcinogens rather and slow conjugation is hypothesized to increase risk by slowly detoxifying or deactivating carcinogens. For analyses of NAT1, NAT1*10 was designated as the at-risk allele based on previous research [38] . The SNPs in NAT1 corresponded to combinations of the following NAT1 alleles: NAT1*10, NAT1*3, NAT1*4, NAT1*11A, NAT1*11B. These allelic combinations were included in the reference group for comparison to the NAT1*10 alleles.
Duplicate samples from 100 study subjects and 40 replicate samples from each of two blood donors were interspersed throughout the plates used for genotype analysis. The concordance rates for quality control samples were 99-100% for all assays. We observed no significant departure from Hardy-Weinberg equilibrium in the control population for any of the SNPs analyzed (p [ 0.05). Demographic characteristics (age, race, and education) for cases and controls did not differ significantly for individuals with undetermined NAT1 and NAT2 alleles compared with those with known NAT1 and NAT2 alleles.
Unconditional logistic regression models were used to estimate the odds ratio (OR) and the 95% confidence interval for associations between cigarette smoking, genetic polymorphisms in NAT1s and NAT2s and risk of NHL, adjusting for age (continuous) and race (white and non-white), and family history. Adjustment for other potential confounding variables, such as education and alcohol use, did not result in material changes of the observed associations, thus they were not included in the final model. Analyses were also conducted for five major histologic subtypes of NHL according to the World Health Organization (WHO) classification: Diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, marginal zone lymphoma, and T-cell lymphoma. All tests were two-sided with significance level of 0.05. All analyses were performed using SAS 8.2 (SAS Institute Inc., Cary, NC).
Results
The association between smoking and NHL in this genotyped population was consistent with the original report [27] . Briefly, of the 535 controls, 53.1% reported ever smoking and 55.7% of the 461 cases reported ever smoking (OR = 1.1; 95% CI: 0.8-1.4; Table 1 ). Of these, 200 cases and 209 controls were former smokers (OR = 1.2; 95% CI: 0.9-1.5), and the remaining 57 cases and 75 controls were current smokers (OR = 0.9; 95% CI 0.6-1.4). No significant variation in risk between cases and controls was observed by race or alcohol use (Table 1) .
No association was observed between NAT1*10 alleles and NHL overall (Table 2) . However, the subtype analyses presented two-fold increased risk among those with heterozygous or homozygous NAT1*10 alleles (OR = 2.0; 95% CI: 1.0-4.2).
NAT2 acetylation phenotypes were not associated with the risk of NHL overall although effects were different between histologic types (p = 0.03; Table 3 ). A threefold increased risk of marginal zone lymphoma (OR = 3.0, 95% CI: 1.0-8.7) and T-cell lymphoma (OR = 3.2, 95% CI: 1.1-9.5) was observed for those with a rapid NAT2 phenotype compared with the slow NAT2 phenotype, though the rapid phenotype group for both subtypes contained only five cases. When the associations with smoking were stratified by NAT1 genotypes and NAT2 phenotypes, a significant increase in risk of NHL overall was observed among current smokers (OR = 1.7, 95% CI: 1.2-2.4) without the NAT1*10 genotype but not among smokers with the NAT1*10 genotype (p-interaction \ 0.01; Table 4 ). The increased risk in smokers without a NAT1*10 genotype was also observed for DLBCL (OR = 1.7, 95% CI: 1.1-2.6) and T-cell lymphoma (OR = 3.8, 95% CI: 1.0-14.1; data not shown). However, no significant alteration in risk was observed for NAT2 by smoking status (p = 0.86).
When the above-mentioned analyses were restricted to non-Hispanic Caucasians, changes in the results were not material (data not shown).
Discussion
Our results present modest evidence that acetylation rate as inferred from NAT2 genotype is associated with risk of NHL for specific subtypes and that the NAT1*10 genotype is an ''at-risk'' allele. Additionally, our results suggest that the relationship between NHL and smoking status may be modified by common genetic variation in NAT1 but not NAT2. Due to small case numbers, our analysis of smoking-genotype interaction focused only on the end point (all NHL).
The role of N-acetyltransferases as important metabolic enzymes is well established in the literature. However, to date, only four studies [30, [40] [41] [42] have evaluated the relationship of NAT1 and NAT2 polymorphisms with NHL risk. The studies by Lemos and Kerridge both reported no Odds ratio (OR) [95% confidence interval (CI)] adjusted for age, race, and family history of NHL p-Interaction reflects the interaction between non-smokers and current smokers*NAT1 or *NAT2 genes; or the interaction between non-smokers and former smokers*NAT1 or *NAT2 genes. The interaction between ever smoking status and *NAT1 genes is 0.0101 and the interaction between ever smoking status and *NAT2 genes is 0.8591 association of NHL with the NAT1 or NAT2 slow acetylation genotypes. However, the more recent studies by Chiu [40] and Morton [30] , both found that the NAT1*10 genotype, where slow acetylation defined as those with NAT*10 alleles, was associated with an increased risk of NHL (only in women in the Chiu et al. study). Although we did not find an association for NHL overall, we did identify a significantly increased risk for T-cell lymphoma and a decreased risk of DLBCL for the NAT1*10 genotype, though the findings were observed in the codominant model only. Our results for DLBCL are consistent with previous work and consistent with the hypothesis that the risk of NHL should decrease if the acetylation rate is slowed. Neither Chiu nor Morton found an association between the NAT2 slow genotype and overall NHL risk in either sex. However, we found a significantly increased risk for marginal zone and T-cell lymphoma with rapid NAT2 acetylation phenotypes, though the case numbers included in our study for these groups was small. Morton et al. noted an increased risk for NAT2 rapid acetylators for the marginal zone and follicular subtypes.
The biologic role of the enzymes suggests that geneenvironment analyses may be a more informative pursuit as their physiologic impact is dependent on the presence of chemicals for metabolism. We observed an association of current smoking with all NHL and the NAT1*10 genotype, though we did not identify any association with either genotype or smoking in the main effects analyses. We did not, however, identify that NAT2 phenotypes modify the association between NHL and NHL subtype by smoking status. Morton et al. found that the risk of NHL associated with current cigarette smoking was observed among NAT2 intermediate and rapid acetylators. They suggested that the variation in acetylation capacity and differential susceptibility to NHL indirectly supports the role of carcinogenic aromatic and/or heterocyclic amines in the etiology of NHL.
Previous studies have suggested that women with the slow acetylation phenotypes for NAT2 may be more adversely affected by tobacco smoking [43] [44] [45] , but the data have been inconsistent [46, 47] . Our results indicate that the NAT1 rapid genotype (without NAT*10 alleles) increases the risk of NHL in smokers relative to the risk observed in non-smokers, indicating that perhaps NAT2 activation (via O-acetylation) may be more important than deactivation (via N-acetylation) in affecting NHL risk or the rapid activation of carcinogens may affect cancer risk more strongly than the slow deactivation or detoxification of carcinogens. This point is strengthened by the results from Morton [30] , which demonstrated a more than twofold in increased risk of NHL in smokers with the rapid NAT2 phenotype.
Our study has several strengths. It is a population-based, case-control study with both incident cases that are histologically confirmed and highly accurate genotyping data. The primary limitation of our study is that the sample size is modest, and the number of cases in several histologic subgroups was small. This resulted in reduced power to detect associations for SNPs with low allele frequencies. It is subsequently not clear whether our subtype findings for the NAT1 genotypes would be observed in the dominant model if more cases were available, or if the finding may be due to chance. Our study was limited to women and may be non-generalizable to the entire population. Further, the response rate in our study is moderate and could potentially result in biased risk estimates if willingness to participate in our study was associated with genotype frequency. However, a recent report observed that subject participation status was unrelated to genotype frequencies for a wide spectrum of genes [48] . Information bias, resulting from exposure misclassification is likely to have been nondifferential, thus biasing our risk estimates toward the null. The positive findings in our report require replication in larger studies with greater power.
In summary, our study suggests that the risk associated with NHL overall appears to be modified by cigarette smoking for those with the NAT1*10 genotype. A detailed, extensive genomic analysis of genes that play a role in the metabolic pathway is warranted in future studies. Further, these findings require replication in larger studies and ultimately in pooled analyses.
